Evidence map›Paper›PMID 41492073›Full record

Trial reportAmerican journal of hematology2026

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Stefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Hänel, Maher Hanoun and 35 more

Abstract readRandomized Controlled TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Stefan Markus DendorferDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.ORCID 0009-0008-4323-521X
Katharina Schmidt-BrückenDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Michael KramerDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Björn SteffenDepartment of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.
Christoph SchliemannDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Jan-Henrik MikeschDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Nael AlakelDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Regina HerbstDepartment of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany.
Mathias HänelDepartment of Internal Medicine III, Chemnitz Hospital, Chemnitz, Germany.
Maher HanounDepartment of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-1754-8940
Martin KaufmannDepartment of Hematology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Barbora WeinbergerovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Kerstin Schäfer-EckartDepartment of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany.
Tim SauerDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Andreas NeubauerDepartment of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany.
Andreas BurchertDepartment of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany.
Claudia D BaldusDepartment of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Jolana MertováInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Edgar JostDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen & CIO ABCD Aachen, RWTH Aachen, Aachen, Germany.
Dirk NiemannDepartment of Hematology, Oncology and Palliative Care, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany.
Jan NovákDepartment of Haematology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Stefan W KrauseDepartment of Internal Medicine V, University Hospital Erlangen, Erlangen, Germany.
Sebastian SchollDepartment of Internal Medicine, University Hospital Jena, Jena, Germany.
Andreas HochhausDepartment of Internal Medicine, University Hospital Jena, Jena, Germany.
Gerhard HeldDepartment of Internal Medicine I, Westpfalzklinikum, Kaiserslautern, Germany.
Tomáš SzotkowskiDepartment of Hemato-Oncology, Palacký University, Olomouc, Czech Republic.
Andreas RankII. Medical Clinic, University Hospital Augsburg, Augsburg, Germany.
Christoph SchmidII. Medical Clinic, University Hospital Augsburg, Augsburg, Germany.
Lars FranseckyDepartment of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Sabine KayserDepartment of Internal Medicine I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.ORCID 0000-0003-3796-8843
Markus SchaichDepartment of Hematology, Oncology and Palliative Care, Rems-Murr-Klinikum, Winnenden, Germany.
Frank FiebigDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Annett HaakeDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Johannes ScheteligDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Jan Moritz MiddekeDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Friedrich StölzelDepartment of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Uwe PlatzbeckerDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Christian ThiedeDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Carsten Müller-TidowDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Wolfgang E BerdelDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Gerhard EhningerDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Jiri MayerDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.ORCID 0000-0003-0567-9887
Hubert ServeDepartment of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.
Martin BornhäuserDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Christoph RölligDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.

Funding

Technische Universität Dresden
6 · The paper itself

Abstract

Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the associated risk for cardiotoxicity remain under debate. The DaunoDouble trial compared daunorubicin at 60 (Dauno60) versus 90 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDaunorubicinLeukemia, Myeloid, AcuteAdolescentAdultAgedBiomarkersCardiotoxicityCytarabineFemaleHumansInduction ChemotherapyMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsBiomarkersCytarabineDaunorubicinNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin Tacute myeloid leukemiaanthracycline chemotherapycardiotoxicitydaunorubicin dosinghigh‐sensitivity troponin T

Identifiers

PMID41492073
PMCPMC12869000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.